Clinical trials: Anthracyclines
Nodal T-follicular Helper Cell Lymphoma
Golidocitinib Plus Anthracycline-based Therapy for Untreated Nodal T-follicular Helper (TFH) Cell Lymphoma
This is a prospective, multicenter, open-label, single-arm, phase II clinical study to evaluate the safety and efficacy of golidocitinib in combination with an anthracycline-based regimen as first-line treatment for patients with…
- Trial name
- NCT07753642
- Testing
- Golidocitinib, Doxorubicin, Epirubicin
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation, as Well as Life Style Intervention
This is an open-label, multicenter, 2x2 factorial design, randomized controlled, Phase III study comparing the disease free survival after randomisation in patients treated with 3 cycles of…
- Trial name
- SUCCESS-C (NCT00847444)
- Testing
- Drug-based intervention, Lifestyle-based Intervention
- Where
- Germany
- Volunteers
- 3,547 people
- Sponsor
- Philip Hepp
Breast Cancer
Monoclonal Antibody Therapy in Treating Women With Locally Advanced or Metastatic Breast Cancer Previously Treated With Combination Chemotherapy
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00066547
- Testing
- monoclonal antibody HuHMFG1
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Metastatic Breast Cancer
A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline
To provide extended access to Ixabepilone therapy to subjects with metastatic breast cancer who have completed the previous Phase II study (CA163-107)
- Trial name
- NCT01027208
- Testing
- Ixabepilone
- Where
- 14 sites in Japan
- Volunteers
- 20 people
- Sponsor
- R-Pharm
Cardiac Complications
Magnetic Resonance Imaging:A Window to Anthracycline Toxicity
The study is being conducted to see which cardiac tests that monitor how the heart functions during and after treatment with anthracyclines are most effective.
- Trial name
- NCT03211520
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Connecticut Children's Medical Center
Acute Myeloid Leukemia
Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia
The combination of clofarabine and cytarabine is an effective and reasonably well-tolerated treatment regimen in patients with either relapsed/refractory or newly diagnosed AML.
- Trial name
- UPCI 13-066 (NCT01960387)
- Testing
- Clofarabine, Cytarabine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Pittsburgh
Breast Cancer
Trastuzumab Administered Concurrently or Sequentially to Anthracycline-containing Adjuvant Regimen for Breast Cancer
Most of the published data support the preferential use of an anthracycline-containing adjuvant regimen for individuals with HER2-positive tumors.
- Trial name
- NCT01413828
- Testing
- concurrent, sequential
- Where
- China
- Volunteers
- 201 people
- Sponsor
- Peking Union Medical College Hospital
Liposarcoma, Leiomyosarcoma
A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
The purpose of this study is to test the safety and effectiveness of an investigational chemotherapy agent in patients with types of advanced cancer referred to as liposarcoma or leiomyosarcoma.
- Trial name
- NCT00060944
- Testing
- Yondelis, Dexamethasone
- Where
- 39 sites in United States, Australia and 6 more
- Volunteers
- 271 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Breast Cancer
Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity
Cardiotoxicity is heart damage that arises from certain drugs, such as those used for cancer treatment and develops in approximately 10% of patients with breast cancer who are treated with anthracyclines.
- Trial name
- SPRINT (NCT07070765)
- Testing
- Sodium-glucose transport-2 (SGLT-2) inhibitors, Standard medical treatment
- Where
- 2 sites in United Kingdom
- Volunteers
- 70 people
- Sponsor
- University of Aberdeen
Breast Cancer
Walking Meditation Exercise in Breast Cancer Patients
This study is to evaluate the effects of Walking Meditation on vascular function in breast cancer patients receiving Anthracyclines chemotherapy
- Trial name
- NCT02676531
- Testing
- Exercise
- Where
- Thailand
- Volunteers
- 30 people
- Sponsor
- Chulalongkorn University
Non-Hodgkins Lymphoma
CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma
This study will assess the toxicity/safety of CHOP chemotherapy given concurrently with rituximab, followed by maintenance PEG Intron in patients with anthracycline naïve indolent non-Hodgkin's lymphoma.
- Trial name
- NCT00574730
- Testing
- CHOP/Rituximab, PEG INTRON
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Nebraska
Heart Failure
Ability of L-carnitine to Prevent Heart Damage in Breast Cancer Patients Receiving Anthracycline Chemotherapy
Breast cancer is very common and afflicts 1 in 9 North American women. The treatment of breast cancer often requires the use of chemotherapy including "anthracyclines".
- Trial name
- NCT00247975
- Testing
- L-carnitine
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Breast Cancer, Cognitive/Functional Effects
Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as doxorubicin and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Cognitive/Functional Effects, Depression, Malnutrition
- Trial name
- NCT00424203
- Testing
- AC regimen, cyclophosphamide, doxorubicin hydrochloride
- Where
- 17 sites in France
- Volunteers
- 40 people
- Sponsor
- UNICANCER
Breast Cancer
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer.
- Trial name
- NCT05748834
- Testing
- Tucatinib, Doxil
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer
Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer
To date no targeted agents are available to treat TNBC. Therefore chemotherapy is the only treatment option. TNBC often has a high amount of tumour infiltrating lymphocytes.
- Trial name
- GeparNuevo (NCT02685059)
- Testing
- MEDI4736 (Anti PD-L1), nab-Paclitaxel, Epirubicin
- Where
- Germany
- Volunteers
- 174 people
- Sponsor
- GBG Forschungs GmbH
Breast Cancer
Carboplatin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00470249
- Testing
- Carboplatin, Gemcitabine Hydrochloride
- Where
- 3 sites in United Kingdom
- Volunteers
- 5 people
- Sponsor
- University of Southampton
Triple Negative Breast Cancer, Breast Cancer
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer
The purpose of this study is to evaluate the mechanism of action, as well as the safety and efficacy of trilaciclib in combination with standard of care treatment in the neoadjuvant setting of early-stage triple negative breast…
- Trial name
- NCT05112536
- Testing
- Trilaciclib, Cylophosphamide, Doxorubicin
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- G1 Therapeutics, Inc.
Breast Cancer
Efficacy and Safety of Non Invasive Vagal Stimulation to Prevent Chemotherapy-induced Nausea
Despite pharmaceutical innovations, chemotherapy induced nausea is frequent and largely participating to alter our patients quality of life.
- Trial name
- SILENCE (NCT04937309)
- Testing
- non invasive auricular vagal stimulation, usual medical treatment
- Where
- 8 sites in France
- Volunteers
- 338 people
- Sponsor
- University Hospital, Tours
Antiemetic Therapy
Epidemiological EMESIS-Registry
The purpose of this registry is to record information on reality of anti-emetic therapies of cancer-patients in Germany. The outcome of this study is the efficacy of anti-emetic therapies dependent on the rate "complete and major…
- Trial name
- EMESIS (NCT00911222)
- Testing
- non-interventional
- Where
- Germany
- Volunteers
- 1,035 people
- Sponsor
- iOMEDICO AG
Ovarian Cancer
NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)
The primary objective of this extension protocol is to evaluate the early safety of a new schedule of NGR-hTNF given weekly, instead of every 3 or 4 weeks, in a cohort of 12 patients randomized to the experimental arm A, as…
- Trial name
- NCT03804866
- Testing
- NGR-hTNF, Pegylated liposomal doxorubicin, Doxorubicin
- Where
- 4 sites in Italy
- Volunteers
- 14 people
- Sponsor
- AGC Biologics S.p.A.